Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 7, 2012

Novartis Reports Positive Phase III Data for Acromegaly Therapy

  • Novartis reported positive data from a Phase III study comparing its somatostatin analog (SSA) pasireotide LAR (long-acting release) with its existing therapy Sandostatin LAR (ocreotide/IM injection) in acromegaly patients. Data from the 358-patient Passport-Acromegaly study showed that 31.3% of pasireotide LAR-treated patients exhibited full disease control (measured as a combination of growth hormone levels and age/sex-matched IGF-1 levels), compared with 19.2% of Sandostatin LAR-treated patients.

    Pasireotide LAR is a multireceptor targeting SSA that binds with high affinity to four of the five somatostatin receptor subtypes (sst 1, 2, 3, and 5). On April 25 the EC approved a subcutaneous formulation of pasireotide, trade-named Signifor®, for the treatment of Cushing disease in adult patients who either aren’t suitable for or have failed surgery. Additional regulatory submissions for the Cushing disease indication are in progress worldwide. 



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »